- Conditions
- Detrusor Hyperreflexia
- Interventions
- Oxybutynin
- Drug
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 15 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Orange County, California • San Diego, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 6,600
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Essential Tremor, Multiple System Atrophy, Corticobasal Degeneration, Supranuclear Palsy, Progressive, Parkinson Disease
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Ulcerative Colitis
- Interventions
- Filgotinib, Placebo
- Drug
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Miami, Florida • Naples, Florida • Columbia, Maryland + 2 more
- Conditions
- Severe Traumatic Brain Injury
- Interventions
- Not listed
- Lead sponsor
- Corewell Health West
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Melanoma (Skin), Metastatic Cancer
- Interventions
- aldesleukin, histamine dihydrochloride
- Biological · Drug
- Lead sponsor
- Maxim Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 11
- States / cities
- Santa Monica, California • Aurora, Colorado • Tampa, Florida + 7 more
- Conditions
- Peripheral Arterial Disease
- Interventions
- Not listed
- Lead sponsor
- Shockwave Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 26
- States / cities
- Palo Alto, California • Aurora, Colorado • Loveland, Colorado + 22 more
- Conditions
- Portal Hypertension, TIPS
- Interventions
- BD Liverty™ TIPS Stent Graft
- Device
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 17
- States / cities
- Palo Alto, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 12 more
- Conditions
- Ischemic Stroke
- Interventions
- MRI
- Device
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Torrance, California
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Bexagliflozin, Placebo
- Drug
- Lead sponsor
- Theracos
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 18
- States / cities
- Canoga Park, California • Chino, California • Huntington Park, California + 15 more
- Conditions
- Herpes Simplex Labialis
- Interventions
- Zicam (Ionic zinc), placebo
- Drug
- Lead sponsor
- Integrative Medicine Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 3
- States / cities
- Tempe, Arizona • Santa Fe, New Mexico • New York, New York
- Conditions
- Neurodegenerative Diseases, sca3, MSA - Multiple System Atrophy, Ataxia, Synucleinopathies
- Interventions
- 18F-PBR06, 18F-PBR06
- Drug · Radiation
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- NHT102, DryNeb
- Drug · Device
- Lead sponsor
- Nob Hill Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Canton, Ohio
- Conditions
- Intensive Care Unit Acquired Weakness, Critical Care, Mechanical Ventilation, Respiratory Failure
- Interventions
- In-Bed Cycle Ergometer, Routine PT
- Device · Other
- Lead sponsor
- McMaster University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Durham, North Carolina
- Conditions
- Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
- Interventions
- Ritlecitinib, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 607 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Encinitas, California • Huntington Beach, California + 31 more
- Conditions
- Aneurysmal Subarachnoid Hemorrhage, Neurobehavioral Manifestations, Vasospasm, Intracranial, Intracranial Aneurysm, Heparin-induced Thrombocytopenia Type II
- Interventions
- Continuous Low-Dose IV Unfractionated Heparin Infusion
- Drug
- Lead sponsor
- Robert F. James
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Gainesville, Florida • Tallahassee, Florida + 6 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- IRL201104, Placebo
- Drug
- Lead sponsor
- Revolo Biotherapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Murrieta, California • Centennial, Colorado + 19 more
- Conditions
- Chronic Heart Failure, Iron Deficiencies
- Interventions
- Ferric Derisomaltose
- Drug
- Lead sponsor
- Pharmacosmos A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Anemia
- Interventions
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • San Diego, California • Detroit, Michigan + 2 more
- Conditions
- Acquired Bleeding Disorder, Trauma
- Interventions
- eptacog alfa (activated), placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
- Interventions
- MEDI4736, Tremelimumab, MEDI4736 + Tremelimumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 96 Years
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Yuma, Arizona • Little Rock, Arkansas + 38 more
- Conditions
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
- Interventions
- Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
- Biological
- Lead sponsor
- AC Immune SA
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more
- Conditions
- 22q11.2 Deletion Syndrome
- Interventions
- NFC-1
- Drug
- Lead sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Community-acquired Pneumonia
- Interventions
- AON-D21, Placebo
- Drug
- Lead sponsor
- Aptarion Biotech AG
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Nausea and Vomiting, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- ondansetron, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more